OncoMatch/Clinical Trials/NCT07247058
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Is NCT07247058 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Osilodrostat (Isturisa) for mild autonomous cortisol secretion (macs).
Treatment: Osilodrostat (Isturisa) — To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, body composition and bone mineral density than at Baseline. The investigators also assess the effect of Isturisa on quality of life and psychological symptoms in patients with MACS. The investigators hypothesize that treatment with Isturisa will lead to significant improvements in quality-of-life scores and reductions in depression scores compared to Baseline.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: glucocorticoids or medications affecting cortisol production (ketoconazole, metyrapone)
Current or recent (within 3 months) treatment with glucocorticoids or medications affecting cortisol production (e.g., ketoconazole, metyrapone)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins University School of Medicine · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify